HMGB1 and hepatocellular carcinoma: So far, to our knowledge, HMGB1 has not been explored as an adjuvant for in situ vaccines for HCC, probably owing to its Janus face in tumorigenesis, TME immunosuppression and DC-T cell crosstalk.